Welcome to our dedicated page for KalVista Pharmaceuticals SEC filings (Ticker: KALV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on KalVista Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into KalVista Pharmaceuticals's regulatory disclosures and financial reporting.
KalVista Pharmaceuticals, Inc. (KALV) – Form 4 insider transaction summary:
- CEO & Director Benjamin L. Palleiko vested 87,500 performance stock units (PSUs) on 07 Jul 2025 after the company met pre-defined performance metrics. Each PSU converted 1:1 into common shares.
- On 09 Jul 2025, Palleiko effected a sale of 32,979 shares at $15.6925 per share. The filing states the sale was solely to satisfy tax-withholding obligations via a “sell-to-cover” mechanism and was not a discretionary trade.
- After the transactions, Palleiko’s direct beneficial ownership stands at 369,595 common shares, a net increase of 54,521 shares versus pre-vesting levels.
The vesting confirms management’s achievement of specified operating or clinical milestones set in January 2023, while the partial sale is procedural. Overall, the filing signals continued insider equity alignment without indicating either bullish or bearish discretionary sentiment.
KalVista Pharmaceuticals (KALV) Form 4: Chief Development Officer Christopher Yea reported two transactions. On 8 July 2025, 60,000 performance stock units (PSUs) vested and converted 1-for-1 into common shares after the company met its performance metrics, raising his direct holdings to 158,189 shares.
On 9 July 2025, Yea executed a Rule 10b5-1 coded S sale of 30,250 shares at an average price of $15.6925 strictly to cover tax-withholding obligations (“sell-to-cover”), leaving him with 127,939 shares.
The net effect is a 29,750-share increase in ownership. No derivative securities were reported. The transactions appear routine and non-discretionary under the company’s equity compensation plan.